Cargando…

PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dölen, Yusuf, Gileadi, Uzi, Chen, Ji-Li, Valente, Michael, Creemers, Jeroen H. A., Van Dinther, Eric A. W., van Riessen, N. Koen, Jäger, Eliezer, Hruby, Martin, Cerundolo, Vincenzo, Diken, Mustafa, Figdor, Carl G., de Vries, I. Jolanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947615/ https://www.ncbi.nlm.nih.gov/pubmed/33717196 http://dx.doi.org/10.3389/fimmu.2021.641703

Ejemplares similares

Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses
por: Dölen, Yusuf, et al.
Publicado: (2020)

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses
por: Dölen, Yusuf, et al.
Publicado: (2015)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1(157-165) tumor-specific peptide
por: Shenderov, Eugene, et al.
Publicado: (2021)

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma
por: Giavina-Bianchi, Mara, et al.
Publicado: (2015)

Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles
por: Operti, Maria Camilla, et al.
Publicado: (2019)

Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion
por: Le Gall, Camille, et al.
Publicado: (2022)

A Dominant Role for the Immunoproteasome in CD8(+) T Cell Responses to Murine Cytomegalovirus
por: Hutchinson, Sarah, et al.
Publicado: (2011)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation
por: Operti, Maria Camilla, et al.
Publicado: (2022)

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
por: McCormack, Emmet, et al.
Publicado: (2012)

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells
por: Pollack, Seth M, et al.
Publicado: (2014)

Translating the Manufacture of Immunotherapeutic PLGA Nanoparticles from Lab to Industrial Scale: Process Transfer and In Vitro Testing
por: Operti, Maria Camilla, et al.
Publicado: (2022)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells
por: Boudousquie, Caroline, et al.
Publicado: (2017)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

NY-ESO-1-Specific Circulating CD4(+) T Cells in Ovarian Cancer Patients Are Prevalently T(H)1 Type Cells Undetectable in the CD25(+)FOXP3(+)Treg Compartment
por: Redjimi, Nassima, et al.
Publicado: (2011)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Förster Resonance Energy Transfer-Based Stability Assessment of PLGA Nanoparticles in Vitro and in Vivo
por: Swider, Edyta, et al.
Publicado: (2019)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer
por: Karbach, Julia, et al.
Publicado: (2023)

Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy
por: Matsuzaki, Junko, et al.
Publicado: (2015)

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
por: Ramachandran, Indu, et al.
Publicado: (2019)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
por: Camisaschi, Chiara, et al.
Publicado: (2018)

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules
por: Bethune, Michael T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_469cic2u1j4l0g9phh4otr0s2q